Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO)/ACTIV-3b - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the study drugs and to see if it can help people with COVID-19 respiratory failure get better and go home faster.

What is the Condition Being Studied?

COVID-19 and Respiratory failure

Who Can Participate in the Study?

Adults who have respiratory failure and have tested positive for COVID-19.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Have a nasal swab
-Give blood samples
-Be randomly assigned to get study drug or a placebo (harmless inactive saline) through a vein in your arm
-Get Remdesivir, an antiviral medication being used to treat COVID-19
-Complete follow-up visits either on the phone or in-person

Study Details

Full Title
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19
Principal Investigator
Heart Surgeon
Protocol Number
IRB: PRO00108134
Phase
Phase III
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698